A Phase 1 interventional study of Herceptin and Sunitinib in Breast Cancer, sponsored by Pfizer. Completed at 7 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-28.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 299th largest by enrollment of the 366 interventional ones that give a count, is one of 18 that started in 2006, is one of 21 in phase 1, and was the 72nd registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 18 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 94th largest by enrollment of the 121 interventional ones that give a count, is one of 9 that started in 2006, is one of 37 in phase 1, and was the 28th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment in the advanced disease setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of SU011248 (37.5 mg once daily \[Schedule 2/1\]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
Drug: Herceptin · Drug: Sunitinib · Drug: Taxotere
Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
Also known as: trastuzumab
SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
Also known as: Sutent
The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
Also known as: docetaxel
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From screening until 28 days post last dose of study drug
Percentage of Participants With Objective Response (OR)
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all target lesions. PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)
Progression-free Survival (PFS)
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)
Duration of Response (DR)
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline, assessed every 6 weeks starting from Day1 of Cycle 3 up to end of treatment (Day 1344)
Plasma Trough Concentrations (Ctrough) of SU011248 (Sunitinib), SU012662 (Sunitinib Metabolite) and Total Drug (SU011248+SU012662)
Ctrough = the concentration prior to study medication administration. Ctrough was calculated for SU011248 (Sunitinib), SU012662 (Sunitinib metabolite) and total drug (SU011248+SU012662). Concentration values below the lower limit of quantification were taken as zero.
Time frame: Pre-dose (0 hours [H]) on Day 1 and Day 15 of Cycle 2, 4, 6 and additionally Day 15 of Cycle 1
Maximum Observed Plasma Concentration (Cmax) of Docetaxel
Concentration values below the lower limit of quantification were taken as zero.
Time frame: End of infusion (1 H) on Day 1 of Cycle 1, 2, 4 and 6
Plasma Trough Concentrations (Ctrough) of Trastuzumab
Ctrough = the concentration prior to study medication administration.
Time frame: Weekly trastuzumab: Pre-dose (0 H) on Day 1 and 15 of Cycle 1, 2, 4 and 6; 3-weekly trastuzumab: Pre-dose (0 H) on Day 1 of Cycle 1, 2, 4 and 6
Maximum Observed Plasma Concentration (Cmax) of Paclitaxel
Time frame: End of infusion (1 H) on Day 1 of Cycle 1, 2, 4 and 6
| Milestone | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Started | 26 |
| Treated | 25 |
| Completed | 0 |
| Not completed | 26 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 1 |
| Withdrew: Objective progression or relapse | 14 |
| Withdrew: Other | 7 |
| Withdrew: Enrolled, not treated | 1 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| AEs | 24 |
| SAEs | 11 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all target lesions. PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| percentage of participants | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Percentage of Participants With Objective Response (OR) | 72.7 (49.8 to 89.3) |
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| weeks | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Progression-free Survival (PFS) | 58.4 (37.0 to 66.1) |
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| weeks | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Duration of Response (DR) | 51.3 (32.0 to 60.1) |
Ctrough = the concentration prior to study medication administration. Ctrough was calculated for SU011248 (Sunitinib), SU012662 (Sunitinib metabolite) and total drug (SU011248+SU012662). Concentration values below the lower limit of quantification were taken as zero.
| nanogram/milliliter (ng/mL) | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Sunitinib: Cycle1/Day15 (n= 19) | 40.17 ± 32.17 |
| Sunitinib: Cycle2/Day1 (n= 17) | 5.96 ± 6.17 |
| Sunitinib: Cycle2/Day15 (n= 16) | 37.29 ± 31.07 |
| Sunitinib: Cycle4/Day1 (n= 17) | 5.26 ± 5.71 |
| Sunitinib: Cycle4/Day15 (n= 16) | 43.21 ± 27.31 |
| Sunitinib: Cycle6/Day1 (n= 16) | 3.36 ± 4.34 |
| Sunitinib: Cycle6/Day15 (n= 13) | 28.46 ± 21.19 |
| Sunitinib Metabolite: Cycle1/Day15 (n= 19) | 16.15 ± 12.09 |
| Sunitinib Metabolite: Cycle2/Day1 (n= 17) | 4.76 ± 3.92 |
| Sunitinib Metabolite: Cycle2/Day15 (n= 16) | 14.43 ± 11.34 |
| Sunitinib Metabolite: Cycle4/Day1 (n= 17) | 3.95 ± 2.57 |
| Sunitinib Metabolite: Cycle4/Day15 (n= 16) | 17.62 ± 11.17 |
| Sunitinib Metabolite: Cycle6/Day1 (n= 16) | 2.96 ± 2.89 |
| Sunitinib Metabolite: Cycle6/Day15 (n= 13) | 11.54 ± 9.66 |
| Total Drug: Cycle1/Day15 (n= 19) | 56.31 ± 42.70 |
| Total Drug: Cycle2/Day1 (n= 17) | 10.72 ± 9.80 |
| Total Drug: Cycle2/Day15 (n= 16) | 51.72 ± 41.45 |
| Total Drug: Cycle4/Day1 (n= 17) | 9.21 ± 7.97 |
| Total Drug: Cycle4/Day15 (n= 16) | 60.83 ± 37.43 |
| Total Drug: Cycle6/Day1 (n= 16) | 6.32 ± 7.02 |
| Total Drug: Cycle6/Day15 (n= 13) | 40.00 ± 30.04 |
Concentration values below the lower limit of quantification were taken as zero.
| ng/mL | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Cycle1/Day1 (n= 23) | 1117.05 ± 1159.53 |
| Cycle2/Day1 (n= 19) | 1388.63 ± 1260.94 |
| Cycle4/Day1 (n= 16) | 1316.88 ± 1096.97 |
| Cycle6/Day1 (n= 15) | 1670.40 ± 1614.07 |
Ctrough = the concentration prior to study medication administration.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sunitinib + Docetaxel + Trastuzumab | — | 11/25 (44%) | 23/25 (92%) |
| Event | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/25 |
| NeutropeniaBlood and lymphatic system disorders | 3/25 |
| DiarrhoeaGastrointestinal disorders | 1/25 |
| Intestinal perforationGastrointestinal disorders | 1/25 |
| Rectal haemorrhageGastrointestinal disorders | 1/25 |
| StomatitisGastrointestinal disorders | 1/25 |
| VomitingGastrointestinal disorders | 1/25 |
| FatigueGeneral disorders | 1/25 |
| Multi-organ failureGeneral disorders | 1/25 |
| ErysipelasInfections and infestations | 1/25 |
| Event | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 15/25 |
| FatigueGeneral disorders | 15/25 |
| NeutropeniaBlood and lymphatic system disorders | 14/25 |
| PyrexiaGeneral disorders | 13/25 |
| NauseaGastrointestinal disorders | 11/25 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 9/25 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/25 |
| Abdominal pain upperGastrointestinal disorders | 7/25 |
| StomatitisGastrointestinal disorders | 7/25 |
| VomitingGastrointestinal disorders | 7/25 |
| Age Continuous(years) | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Mean | 57.0 ± 12.8 |
| Sex: Female, Male(Participants) | Sunitinib + Docetaxel + Trastuzumab |
|---|---|
| Female | 25 |
| Male | 0 |
The record gives a start of Dec 2006, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab · Docetaxel